Aligos Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 23 quarters of results from Dec 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||||||||||
| EBT Margin | -2,146.91% | -10,292.10% | -1,383.20% | -538.23% | -454.55% | -617.39% | -887.19% | -419.98% | -836.21% | -1,389.85% | -5,020.03% | 494.82% | -1,533.44% | -13,551.65% | 13,868.49% | -1,624.66% | -4,248.45% | -11,746.15% | -802.93% | ||||
| EBIT Margin | -2,151.46% | -10,340.05% | -1,383.00% | -552.21% | -461.47% | -641.28% | -925.98% | -445.76% | -885.38% | -1,294.03% | -3,176.66% | -2,489.54% | -1,610.48% | -3,393.23% | -6,187.46% | -1,924.04% | -3,827.40% | -12,907.69% | -951.55% | ||||
| EBITDA Margin | -2,151.46% | -10,340.05% | -1,383.00% | -552.21% | -461.47% | -641.28% | -925.98% | -445.76% | -885.38% | -1,294.03% | -3,176.66% | -2,489.54% | -1,610.48% | -3,393.23% | -6,187.46% | -1,924.04% | -3,827.40% | -12,907.69% | -951.55% | ||||
| Operating Margin | -2,151.46% | -10,340.05% | -1,383.00% | -552.21% | -461.47% | -641.28% | -925.98% | -445.76% | -885.38% | -1,294.03% | -3,176.66% | -2,489.54% | -1,610.48% | -3,393.23% | -6,187.46% | -1,924.04% | -3,827.40% | -12,907.69% | -951.55% | ||||
| Net Margin | -2,155.11% | -10,276.29% | -1,385.26% | -539.51% | -453.51% | -618.77% | -888.70% | -437.61% | -837.56% | -1,388.35% | -5,023.49% | 477.00% | -1,540.72% | -13,556.11% | 13,854.66% | -1,643.83% | -4,256.01% | -8,610.65% | -814.13% | ||||
| FCF Margin | -1,656.80% | -10,304.09% | -814.82% | -686.95% | -417.44% | -477.07% | -866.98% | -317.09% | -944.10% | -1,127.82% | -3,277.52% | -1,837.23% | -1,608.08% | -3,036.80% | -6,723.15% | -1,606.63% | -3,285.43% | -12,866.86% | -817.24% | ||||
| Efficiency | |||||||||||||||||||||||
| Assets AverageAssets Avg. | 0.24B | 0.25B | 0.22B | 0.20B | 0.17B | 0.16B | 0.13B | 0.11B | 0.10B | 0.12B | 0.14B | 0.12B | 0.10B | 0.08B | 0.11B | 0.14B | 0.12B | 0.10B | 0.08B | 0.07B | |||
| Asset Utilization RatioAsset Util. | 0.02 | 0.03 | 0.04 | 0.06 | 0.09 | 0.10 | 0.13 | 0.13 | 0.09 | 0.07 | 0.05 | 0.05 | 0.05 | 0.03 | 0.02 | 0.02 | 0.02 | 0.06 | 0.06 | ||||
| Valuation | |||||||||||||||||||||||
| Price to EarningsP/E | -498.81 | -335.91 | -64.44 | -64.99 | -63.23 | -46.74 | -40.87 | -56.19 | -45.02 | -38.24 | -109.74 | 270.48 | -2.82 | -3.04 | 1.61 | -4.70 | -3.22 | -6.33 | -3.35 | -40.02 | |||
| Price to SalesP/S | 0.00B | 0.00B | 892.60 | 350.65 | 286.76 | 289.19 | 363.24 | 245.88 | 377.06 | 530.97 | 0.00B | 0.00B | 43.45 | 411.85 | 223.05 | 77.34 | 137.14 | 545.13 | 27.31 | ||||
| Price to BookP/B | 76.14 | 68.58 | 15.01 | 9.45 | 9.65 | 9.84 | 11.07 | 15.16 | 14.82 | 11.58 | 63.98 | 20.36 | 1.08 | -8.61 | 0.60 | 0.73 | 1.41 | 1.72 | 2.43 | 1.89 | |||
| Enterprise Value | 16.28B | 12.48B | 2.11B | 1.14B | 1.04B | 0.90B | 0.83B | 0.96B | 0.74B | 0.93B | 3.62B | 1.22B | -0.06B | 0.19B | -0.13B | -0.15B | -0.05B | 0.01B | -0.00B | 0.03B | |||
| EV to EBIT | -492.34 | -328.81 | -59.39 | -55.69 | -54.63 | -39.55 | -34.90 | -50.41 | -38.89 | -35.81 | -164.41 | -46.37 | 2.99 | -9.37 | 6.89 | 8.22 | 1.93 | -0.65 | 0.09 | -15.74 | |||
| EV to EBITDA | -492.34 | -328.81 | -59.39 | -55.69 | -54.63 | -39.55 | -34.90 | -50.41 | -38.89 | -35.81 | -164.41 | -46.37 | 2.99 | -9.37 | 6.89 | 8.22 | 1.93 | -0.65 | 0.09 | -15.74 | |||
| Market Capitalization | 16.52B | 12.67B | 2.29B | 1.29B | 1.18B | 1.02B | 0.94B | 1.06B | 0.81B | 1.07B | 3.83B | 1.37B | 0.05B | 0.25B | 0.07B | 0.07B | 0.10B | 0.09B | 0.08B | 0.06B | |||
| Price to FCFP/FCF | -648.84 | -335.00 | -109.55 | -51.04 | -68.69 | -60.62 | -41.90 | -77.54 | -39.94 | -47.08 | -168.20 | -70.22 | -2.70 | -13.56 | -3.32 | -4.81 | -4.17 | -4.24 | -3.34 | -2.41 | |||
| EV to FCF | -639.33 | -329.96 | -100.80 | -44.76 | -60.39 | -53.16 | -37.27 | -70.87 | -36.47 | -41.09 | -159.35 | -62.84 | 2.99 | -10.47 | 6.34 | 9.84 | 2.24 | -0.66 | 0.11 | -1.19 | |||
| EV to CFO | -641.78 | -332.91 | -103.34 | -45.36 | -60.40 | -53.45 | -37.29 | -70.87 | -36.47 | -41.09 | -159.35 | -62.84 | 2.99 | -10.47 | 6.34 | 9.84 | 2.24 | -0.66 | 0.11 | -1.19 | |||
| Return Ratios | |||||||||||||||||||||||
| Return on Sales [ROS]ROS | -2,151.46% | -10,340.05% | -1,383.00% | -552.21% | -461.47% | -641.28% | -925.98% | -445.76% | -885.38% | -1,294.03% | -3,176.66% | -2,489.54% | -1,610.48% | -3,393.23% | -6,187.46% | -1,924.04% | -3,827.40% | -12,907.69% | -951.55% | -2,112.14% | |||
| Return on Capital Employed [ROCE]ROCE | -61.50% | -61.03% | -74.98% | -77.02% | -79.05% | -79.82% | -80.97% | -97.67% | -115.35% | -92.98% | -71.38% | -98.67% | -121.79% | -154.99% | -94.43% | -64.12% | -86.52% | -112.92% | -179.75% | -212.92% | |||
| Return on Assets [ROA]ROA | -52.65% | -51.49% | -61.13% | -64.32% | -64.56% | -61.81% | -62.13% | -72.19% | -85.08% | -73.87% | -71.28% | -63.99% | -78.03% | -165.55% | -48.24% | -51.99% | -70.73% | -19.03% | -111.03% | -107.93% |